Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults. In an early-stage clinical trial led by the Dana-Farber Cancer Institute in Boston,

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5.

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses and keeping patients cancer-free for years.

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small early-stage trial, researchers reported in Nature.